The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Open accessAbstract
BACKGROUND: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease. METHODS: We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76×10(6) to 20.6×10(6) CTL019 cells per kilogram of body weight. Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells. RESULTS: A total of 30 children and adults received CTL019. Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation. CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response. Sustained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95). At 6 months, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94). All the patients had the cytokine-release syndrome. Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab. CONCLUSIONS: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. (Funded by Novartis and others; CART19 ClinicalTrials.gov numbers, NCT01626495 and NCT01029366.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, as with TCRs, the adverse effects of CAR T-cell therapy appear to be mechanism based and not a result of using viral vectors [74].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The anti-IL-6R antibodies tocilizumab and sarilumab are used to treat RA, Castleman’s disease and CAR-T-induced CRS (71–75, 352, 364) and have promise for treating the severe form of COVID-19 (365–367).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [364]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinical trials using CD19-targeted CAR T-cell therapy for B-cell acute lymphoblastic leukemia have demonstrated high efficacy, with durable complete response rates in >60% of patients with relapsed or refractory disease [74, 75].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“One important on-target side effect of CD19 CAR T-cell therapy is B-cell aplasia, which is associated with long-term CAR T-cell persistence [74].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“The anti-IL-6R antibody tocilizumab is effective at treating patients with CAR-T-induced cytokine release syndrome (CRS) (352, 364) and is being considered for treating ARDS in COVID-19 patients (365–368).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [364]
In the citing paper
“In patients who received tocilizumab, severe clinical manifestations rapidly improved 1–3 days after injection (Maude et al., 2014”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Maude et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Self-citationBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,032
Pagliaro, L., Chen, S., Herranz, D., Mecucci, C., Harrison, C. J., Mullighan, C. G., Zhang, M., Zhu, C. H., Boissel, N., Winter, S. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00525-x · Cited by 202
New cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
Yu, J., Wu, X., Yan, J., Yu, H., Xu, L., Chi, Z., Sheng, X., Si, L., Cui, C., Dai, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0548-2 · Cited by 191
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Ramakrishna, S., Highfill, S. L., Walsh, Z. H., Nguyen, S. M., Lei, H., Shern, J. F., Qin, H., Kraft, I. L., Stetler‐Stevenson, M., Yuan, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3784 · Cited by 188
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016) · Journal of Immunology Research · doi:10.1155/2016/5474602 · Cited by 186
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Fousek, K., Watanabe, J., Joseph, S. K., George, A., An, X., Byrd, T. T., Morris, J. S., Luong, A., Martinez-Paniagua, M. A., Sanber, K. S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0792-2 · Cited by 189
Aberrant RNA Splicing in Cancer and Drug Resistance
Wang, B., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 183
Lickefett, B., Chu, L., Ortiz‐Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D. A., Hudecek, M., Kremer, A., Markman, J. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 200
Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182
Self-citationWilliams, B. A., Law, A., Routy, B., denHollander, N., Gupta, V. K., Wang, X., Chaboureau, A., Viswanathan, S., & Keating, A. (2017) · Oncotarget · doi:10.18632/oncotarget.19204 · Cited by 180
Mata, M., Gerken, C. P., Nguyen, P., Krenciute, G., Spencer, D. M., & Gottschalk, S. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0263 · Cited by 181
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 182
“Likewise, the faster kinetics of effector function reported in preclinical studies may be mirrored by the observation that CAR T cell persistence did not correlate with the survival of patients in a trial utilizing CD28-containing second-generation CAR T cells to treat ALL [24].”
BackgroundResultInfluentialCytokine Release Syndrome: Current Perspectives
Murthy, H. S., Iqbal, M., Chávez, J. C., & Kharfan‐Dabaja, M. A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s202015 · Cited by 188
“led to the approval of tocilizumab for treatment of CRS concurrent with the approval of tisagenlecleucel.(23,24) The”
BackgroundFrey, N. V., Gill, S. I., Hexner, E. O., Schuster, S. J., Nasta, S. D., Loren, A. W., Svoboda, J., Stadtmauer, E. A., Landsburg, D. J., Mato, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03237 · Cited by 181
“Prior use of venetoclax 1 (3) 1 (5) 0 (0) Lymphocytes in bone marrow at enrollment, median (range), % 60 (5-95) [n 5 21] 64.”
BackgroundSelf-citationBillingsley, M. M., Hamilton, A. G., Mai, D., Patel, S. K., Swingle, K. L., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02503 · Cited by 188
Self-citationVitanza, N. A., Ronsley, R. J., Choe, M., Seidel, K. D., Huang, W., Rawlings-Rhea, S. D., Beam, M., Steinmetzer, L., Wilson, A. L., Brown, C. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03451-3 · Cited by 190
Ribas, A., Medina, T., Kirkwood, J. M., Zakharia, Y., Gonzalez, R., Davar, D., Chmielowski, B., Campbell, K. M., Bao, R., Kelley, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0425 · Cited by 180
“The TLR4 and TLR7/8 agonists resulted in the strongest induction of interleukin (IL)-6, a proinflammatory cytokine implicated in AEs, including cytokine release syndromes (16), compared with all TLR9 agonists assessed (Supplementary Fig.”
BackgroundKueberuwa, G., Kalaitsidou, M., Cheadle, E. J., Hawkins, R. E., & Gilham, D. E. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.12.003 · Cited by 180
Kagoya, Y., Guo, T., Yeung, B., Saso, K., Anczurowski, M., Wang, C.-H., Murata, K., Sugata, K., Saijo, H., Matsunaga, Y., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0508 · Cited by 184
Current Progress in CAR-T Cell Therapy for Hematological Malignancies
Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2020) · Journal of Cancer · doi:10.7150/jca.48976 · Cited by 184
“In this section, the latest study and application of the CAR-T cell therapy in leukemia, lymphoma and multiple myeloma were introduced[13].”
BackgroundHu, Y., Sun, J., Wu, Z., Yu, J., Cui, Q., Pu, C., Liang, B., Luo, Y., Shi, J., Jin, A., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0299-5 · Cited by 180
Yin, Y., Boesteanu, A. C., Binder, Z. A., Xu, C. B., Reid, R. A., Rodriguez, J. L., Cook, D. R., Thokala, R., Blouch, K., McGettigan-Croce, B., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.08.002 · Cited by 186
Self-citationHay, K. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15644 · Cited by 177
Liu, Y., Guo, Y., Wu, Z., Feng, K., Tong, C., Wang, Y., Dai, H., Shi, F., Yang, Q., & Han, W. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.04.088 · Cited by 179
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 178
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhao, Z., Zheng, L., Chen, W., Weng, W., Song, J., & Ji, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0817-3 · Cited by 183
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94952 · Cited by 175
Self-citationCAR T Cell Toxicity: Current Management and Future Directions
Yáñez, L., Sánchez‐Escamilla, M., & Perales, M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000186 · Cited by 180
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Roex, G., Timmers, M., Wouters, K., Campillo-Davó, D., Flumens, D., Schroyens, W., Chu, Y., Berneman, Z. N., Lion, E., Luo, F., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01001-1 · Cited by 189
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Khaw, S. L., Suryani, S., Evans, K., Richmond, J., Robbins, A. K., Kurmasheva, R. T., Billups, C. A., Erickson, S. W., Guo, Y., Houghton, P. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707414 · Cited by 176
Redirecting T cells to hematological malignancies with bispecific antibodies
Velasquez, M. P., Bonifant, C. L., & Gottschalk, S. M. (2017) · Blood · doi:10.1182/blood-2017-06-741058 · Cited by 176
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lee, L. S. H., Draper, B., Chaplin, N., Philip, B., Chin, M., Galas‐Filipowicz, D., Onuoha, S. C., Thomas, S., Baldan, V., Bughda, R., et al. (2017) · Blood · doi:10.1182/blood-2017-05-781351 · Cited by 180
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo
Kooreman, N. G., Kim, Y., de Almeida, P. E., Termglinchan, V., Diecke, S., Shao, N., Wei, T.-T., Yi, H., Dey, D., Nelakanti, R. V., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.016 · Cited by 173
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Cao, J., Wang, G., Cheng, H., Wei, C., Qi, K., Sang, W., Li, Z., Shi, M., Li, H., Qiao, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25108 · Cited by 176
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R. F., Kuball, J. H. E., Lankester, A. C., Montoto, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0465-9 · Cited by 174
Chichili, G. R., Huang, L., Li, H., Burke, S., He, L., Tang, Q., Jin, L. X., Gorlatov, S. N., Ciccarone, V. C., Chen, F., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5693 · Cited by 173
CAR-T Cell Therapy for Lymphoma
Ramos, C. A., Heslop, H. E., & Brenner, M. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051914-021702 · Cited by 178
Cardiovascular Effects of CAR T Cell Therapy
Lefebvre, B., Kang, Y., Smith, A. M., Frey, N. V., Carver, J. R., & Scherrer‐Crosbie, M. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.04.012 · Cited by 177
“The median age (60 years), male distribution (74%), and distribution of malignancies (25% ALL, 30% DLBCL, and 46% CLL) are representative of the current population receiving CAR T cell therapy (15,16).”
BackgroundInfluentialSelf-citationBai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Self-citationRedirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules
Kim, M. S., Ma, J. S. Y., Yun, H., Cao, Y. J., Kim, J. Y., Chi, V., Wang, D., Woods, A. C., Sherwood, L., Caballero, D., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b00106 · Cited by 170
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Zheng, P., Kros, J. M., & Li, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.012 · Cited by 178
Current Immunotherapies for Glioblastoma Multiforme
Huang, B., Li, X., Li, Y., Zhang, J., Zong, Z., & Zhang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603911 · Cited by 183
CAR T-cell therapy for multiple myeloma: state of the art and prospects
van de Donk, N. W. C. J., Usmani, S. Z., & Yong, K. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00057-0 · Cited by 171
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, M.-E., & Bargou, R. C. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1161185 · Cited by 178
Lamers, C. H. J., Klaver, Y., Gratama, J. W., Sleijfer, S., & Debets, R. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160037 · Cited by 170
Abboud, R., Keller, J., Slade, M., DiPersio, J. F., Westervelt, P., Rettig, M. P., Meier, S., Fehniger, T. A., Abboud, C. N., Uy, G. L., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.010 · Cited by 171
Shalabi, H., Kraft, I. L., Wang, H., Yuan, C. M., Yates, B., Delbrook, C., Zimbelman, J. D., Giller, R., Stetler‐Stevenson, M., Jaffe, E. S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183459 · Cited by 170
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Hu, Y., Tian, Z., & Zhang, C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.125 · Cited by 170
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
Westin, J. R., & Sehn, L. H. (2022) · Blood · doi:10.1182/blood.2022015789 · Cited by 177
Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity
Tsukamoto, H., Fujieda, K., Senju, S., Ikeda, T., Oshiumi, H., & Nishimura, Y. (2017) · Cancer Science · doi:10.1111/cas.13433 · Cited by 168
Henderson, L. A., & Cron, R. Q. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00367-1 · Cited by 168
Tasian, S. K., Kenderian, S. S., Shen, F., Ruella, M., Shestova, O. E., Kozlowski, M. S., Li, Y., Schrank-Hacker, A. M., Morrissette, J. J. D., Carroll, M. P., et al. (2017) · Blood · doi:10.1182/blood-2016-08-736041 · Cited by 172
Self-citationSyk inhibitors in clinical development for hematological malignancies
Liu, D., & Mamorska-Dyga, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0512-1 · Cited by 175
Priceman, S. J., Gerdts, E. A., Tilakawardane, D., Kennewick, K. T., Murad, J. P., Park, A. K., Jeang, B., Yamaguchi, Y., Yang, X., Urak, R. Z., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1380764 · Cited by 170
Inefficient CAR-proximal signaling blunts antigen sensitivity
Gudipati, V., Rydzek, J., Perez, I. D., Gonçalves, V. D. R., Scharf, L., Königsberger, S., Lobner, E., Kunert, R., Einsele, H., Stockinger, H. S. J., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0719-0 · Cited by 175
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh, M., Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0101 · Cited by 189
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027469 · Cited by 168
Bednarski, J. J., Zimmerman, C., Berrien-Elliott, M. M., Foltz, J. A., Becker‐Hapak, M., Neal, C. C., Foster, M., Schappe, T., McClain, E. D., Pence, P., et al. (2021) · Blood · doi:10.1182/blood.2021013972 · Cited by 174
Li, W., Qiu, S., Chen, J., Jiang, S., Chen, W., Jiang, J., Wang, F., Si, W., Shu, Y., Wei, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.011 · Cited by 167
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
Genetically modified T cells in cancer therapy: opportunities and challenges
Sharpe, M. E., & Mount, N. M. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018036 · Cited by 172
Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression
Patil, N. K., Bohannon, J. K., & Sherwood, E. R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.019 · Cited by 173
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Bufalo, F. D., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 166
Hill, J. A., Giralt, S., Torgerson, T. R., & Lazarus, H. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100596 · Cited by 170
“Thus, many patients who receive CAR-T cell therapy have already experienced significant toxicity and morbidity from their underlying disease and prior treatments.[5-8, 10-12]”
BackgroundInfluentialTashiro, H., Sauer, T., Shum, T., Parikh, K., Mamonkin, M., Omer, B. A., Rouce, R. H., Lulla, P., Rooney, C. M., Gottschalk, S. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.024 · Cited by 162
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 164
Woan, K. V., Kim, H., Bjordahl, R., Davis, Z., Gaidarova, S., Goulding, J., Hancock, B., Mahmood, S., Abujarour, R., Wang, H.-B., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.08.013 · Cited by 144
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
Jo, S., Das, S., Williams, A., Chrétien, A.-S., Pagliardini, T., Roy, A. L., Postigo, J., Clerre, D. L., Jahangiri, B., Chion-Sotinel, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30896-2 · Cited by 167
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Pan, J., Zuo, S., Deng, B., Xu, X., Li, C., Zheng, Q., Ling, Z., Song, W., Xu, J., Duan, J., et al. (2019) · Blood · doi:10.1182/blood.2019003293 · Cited by 164
Liu, S., Deng, B., Yin, Z., Pan, J., Lin, Y., Ling, Z., Wu, T., Chen, D., Chang, A. H., Gao, Z., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0280-y · Cited by 159
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Salter, A. I., Pont, M. J., & Riddell, S. R. (2018) · Blood · doi:10.1182/blood-2018-01-785840 · Cited by 166
One-step generation of modular CAR-T cells with AAV–Cpf1
Dai, X., Park, J. J.-Y., Du, Y., Kim, H. R., Wang, G., Errami, Y., & Chen, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0329-7 · Cited by 161
Wu, X., Luo, H., Shi, B., Di, S., Sun, R., Su, J., Liu, Y., Li, H., Jiang, H., & Li, Z. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.020 · Cited by 162
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Felsenstein, K. M., & Theodorescu, D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.179 · Cited by 159
Yuan, J., Cai, T., Zheng, X., Ren, Y., Qi, J., Lü, X., Chen, H., Lin, H., Chen, Z., Liu, M., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00821-2 · Cited by 168
“…like immune checkpoint blockade (ICB), targeting PD-1 and CTLA4, and chimeric antigen receptor T (CAR-T) cell therapy, both of which have been approved for the treatment of a variety of cancers (Ishida et al., 1992; Leach et al., 1996; Morgan et al., 2006; Wolchok et al., 2013; Maude et al., 2014).”
BackgroundManufacturing chimeric antigen receptor T cells: issues and challenges
Roddie, C., O'Reilly, M., Dias Alves Pinto, J., Vispute, K., & Lowdell, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.009 · Cited by 168
Kaufmann, P., Pariser, A., & Austin, C. P. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0936-x · Cited by 169
Optimizing CAR-T cell manufacturing processes during pivotal clinical trials
Tyagarajan, S., Spencer, T., & Smith, J. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.018 · Cited by 161
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Bobisse, S., Genolet, R., Roberti, A., Tanyi, J. L., Racle, J., Stevenson, B. J., Iseli, C., Michel, A., Bitoux, M. L., Guillaume, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03301-0 · Cited by 165
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Subklewe, M. S., von Bergwelt‐Baildon, M., & Humpe, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000496870 · Cited by 161
Current challenges and emerging opportunities of CAR-T cell therapies
Abreu, T. R., Fonseca, N. A., Gonçalves, N., & Moreira, J. N. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.047 · Cited by 159
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
Saltos, A. N., Shafique, M. R., & Chiappori, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01074 · Cited by 160
“A variation on ACT known as chimericantigen receptor T cell (CAR-T) therapy involves engineered Tcells with tumor-antigen specificity and has recently been widely employed with significant success in hematologic malignancies, including acute lymphoblastic leukemia (89).”
BackgroundNanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 160
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Sun, S., He, H., Yang, G., Zhang, Y., & Fu, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/2386187 · Cited by 163
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 165
“A durable remission was achieved in 24 months with overall survival (OS) rate of 78% (95% CI, 65 to 95) and a 6-month event-free survival (EFS) rate of 68% (95% CI, 50 to 92) [38].”
Backgroundfor the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Basak, G. W., Bonini, C., Duarte, R. F., Dufour, C., Kröger, N. M., Kuball, J. H. E., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0153-1 · Cited by 159
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N. J., Abate‐Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 163
A new era of cancer phototherapy: mechanisms and applications
Wang, Y., Ma, K., Kang, M., Yan, D., Niu, N., Yan, S., Sun, P., Zhang, L., Sun, L., Wang, D., et al. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00708e · Cited by 162
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
“The cellular kinetics of CAR T cells and tumor burden are two important factors affecting the efficacy of CAR T-cell therapy in B-ALL (15, 20).”
BackgroundRafiq, S., Purdon, T. J., Daniyan, A. F., Koneru, M., Dao, T., Liu, C., Scheinberg, D. A., & Brentjens, R. J. (2016) · Leukemia · doi:10.1038/leu.2016.373 · Cited by 157
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 152
CAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 159
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Guedan, S., & Alemany, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02460 · Cited by 158
Hinner, M. J., Aiba, R. S. B., Jaquin, T. J., Berger, S., Dürr, M. C., Schlosser, C. S., Allersdorfer, A., Wiedenmann, A., Matschiner, G., Schüler, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3654 · Cited by 158
“4-1BB signaling for a sustained and successful anticancer T-cell response is provided in ACT with chimeric antigen receptors (CAR), where inclusion of 4-1BB–signaling elements in the cytoplasmic domain of CARs has been found to improve durability of clinical responses (17, 18).”
BackgroundDevelopments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 158
Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151
Self-citationHummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Metadata
- Authors
- Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Abramson Cancer Center (US)
- University of Pennsylvania (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-10-16
- Volume
- 371
- Issue
- 16
- Pages
- 1507-1517
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4267531
- OpenAlex
- W2118796952
- Cited by
- 5,413
- References
- 30
- Citations by year
- 2026: 228 · 2025: 318 · 2024: 378 · 2023: 505 · 2022: 495 · 2021: 558 · 2020: 665 · 2019: 538 · 2018: 501 · 2017: 541 · 2016: 385 · 2015: 261 · 2014: 24
- FWCI
- 195.01
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-03-10)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Children's Hospital of Philadelphia
- St. Jude Children's Research Hospital
- School of Medicine, Indiana University
- National Cancer Institute (P30CA147859, R01CA165206, R01CA102646, R01CA116660, T32CA009615, P30CA016520)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- chimeric antigen receptor T cells, CD19, acute lymphoblastic leukemia, relapsed/refractory leukemia, CAR T-cell therapy, tisagenlecleucel, lentiviral vectors, complete remission, cytokine release syndrome, tocilizumab, B-cell aplasia, stem cell transplantation, event-free survival, sustained remission, pediatric and adult patients
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Female, Genetic Engineering, Genetic Vectors, Humans, Immunotherapy, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Genetic Therapy, Survival Rate, Lentivirus, Cytokines, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
